Building the Future of Compliance-Driven Drug Screening
Market Opportunity
Workplace Safety in cannabis authorized regions
Public safety in zero- tolerance jurisdictions
Multi-drug detection expands global market potential
Technology Overview
The science behind compliance
SpectraCann’s platform is built on advanced integrated photonic detection technology, offering parts-per-trillion sensitivity designed to identify specific molecular signatures in collected samples.
Unlike traditional testing approaches, SpectraCann focuses on:
- Targeted VOC detection
- High sensitivity for selected VOCs
- Rapid analysis suitable for operational deployment
- Scalable solution architecture
A Competitive Edge in Compliance-Focused Testing
SpectraCann delivers rapid, non-invasive drug screening designed to meet jurisdiction-specific regulatory requirements. Our Targeted detection approach focuses on what regulators actually care about, giving organizations timely, actionable results while maintaining safety and compliance.
Traditional testing approaches, in contrast, often involve:
- Invasive sample collection – requiring urine, blood, or saliva tests that can be uncomfortable and impractical in the field.
- Delay laboratory processing – waiting hours or days for results, slowing critical compliance decisions.
- Broad-spectrum detection – measures many substances, including some that aren’t relevant to regulations, producing results that can be confusing and not aligned with client compliance needs.
Platform Roadmap
The platform architecture is designed to support:
- Multiple VOCs and target drugs
- Evolving regulatory standards
- Additional compliance-driven applications
This approach positions SpectraCann as a scalable compliance platform rather then a single-product solution.
Platform Vision
Adaptable to differing compliance requirements
Designed for operational deployment
Scalable and
future ready
Contact us about opportunities to invest in SpectraCann
Many thanks to our supporters from close to home and around the world.
